Edition:
India

aTyr Pharma Inc (LIFE.OQ)

LIFE.OQ on NASDAQ Stock Exchange Capital Market

3.93USD
20 Sep 2019
Change (% chg)

$0.21 (+5.65%)
Prev Close
$3.72
Open
$3.85
Day's High
$3.93
Day's Low
$3.85
Volume
2,294
Avg. Vol
16,148
52-wk High
$12.32
52-wk Low
$2.79

Latest Key Developments (Source: Significant Developments)

Atyr Posts Qtrly Loss Per Share Of $1.80
Wednesday, 14 Aug 2019 

Aug 14 (Reuters) - aTyr Pharma Inc ::ATYR PHARMA ANNOUNCES SECOND QUARTER 2019 RESULTS AND PROVIDES CORPORATE UPDATE.QTRLY LOSS PER SHARE $1.80.AS OF JUNE 30, 2019, ATYR HAD $42.4 MILLION IN CASH, CASH EQUIVALENTS AND INVESTMENTS.TO REPORT INTERIM SAFETY RESULTS FROM PHASE 1B/2A PROOF-OF-CONCEPT TRIAL OF ATYR1923 IN PULMONARY SARCOIDOSIS PATIENTS IN Q4 2019.  Full Article

Atyr Pharma Announces Reverse Stock Split To Regain Nasdaq Compliance
Saturday, 29 Jun 2019 

June 28 (Reuters) - aTyr Pharma Inc ::ATYR PHARMA ANNOUNCES REVERSE STOCK SPLIT TO REGAIN NASDAQ COMPLIANCE.ANNOUNCES 1 FOR 14 REVERSE STOCK SPLIT.PAR VALUE OF COMPANY'S COMMON STOCK WILL REMAIN UNCHANGED AT $0.001 PER SHARE AFTER REVERSE STOCK SPLIT.ONE-FOR-14 REVERSE STOCK SPLIT IS SCHEDULED TO BECOME EFFECTIVE AFTER TRADING CLOSES ON JUNE 28, 2019.  Full Article

Atyr Pharma Announces Fourth Quarter Results
Tuesday, 26 Mar 2019 

March 25 (Reuters) - aTyr Pharma Inc ::ATYR PHARMA ANNOUNCES FOURTH QUARTER AND FULL YEAR 2018 RESULTS AND PROVIDES CORPORATE UPDATE.ATYR PHARMA INC - AS OF DECEMBER 31, 2018, ATYR HAD $49.5 MILLION IN CASH, CASH EQUIVALENTS AND INVESTMENTS.ATYR PHARMA - AS OF DEC 31, 2018, CO HAD $49.5 MILLION IN CASH, CASH EQUIVALENTS & INVESTMENTS.ATYR PHARMA INC - FOR 2019, CO PROJECTING CASH BURN OF ABOUT $23 MILLION TO $25 MILLION, NET OF DEBT.  Full Article

aTyr Pharma Announces Third Quarter 2018 Operating Results
Wednesday, 14 Nov 2018 

Nov 13 (Reuters) - aTyr Pharma Inc ::ATYR PHARMA ANNOUNCES THIRD QUARTER 2018 OPERATING RESULTS AND PROVIDES CORPORATE UPDATE.ATYR PHARMA INC - INITIATION OF PROOF-OF-CONCEPT STUDY IN PATIENTS WITH PULMONARY SARCOIDOSIS PLANNED FOR Q4 OF 2018.ATYR PHARMA INC - QTRLY LOSS PER SHARE $0.24.  Full Article

Paul Schimmel Reports A 5.3 Pct Stake In Atyr Pharma As Of Aug. 30
Tuesday, 11 Sep 2018 

Sept 10 (Reuters) - aTyr Pharma Inc ::AS OF AUG. 30 - SEC FILING.PAUL SCHIMMEL SAYS ACQUIRED ATYR PHARMA'S SHARES FOR INVESTMENT ON BELIEF THAT SUCH SHARES REPRESENTED "AN ATTRACTIVE INVESTMENT OPPORTUNITY".  Full Article

Atyr Pharma Q4 Loss Per Share $0.39
Tuesday, 20 Mar 2018 

March 19 (Reuters) - Atyr Pharma Inc ::ATYR PHARMA ANNOUNCES FOURTH QUARTER AND YEAR-END 2017 OPERATING RESULTS AND PROVIDES CORPORATE UPDATE.‍ATYR EXPECTS THAT ITS CASH, CASH EQUIVALENTS AND INVESTMENTS WILL BE SUFFICIENT TO FUND ITS ANTICIPATED OPERATIONS INTO Q3 OF 2019​.QTRLY LOSS PER SHARE $0.39.Q4 EARNINGS PER SHARE VIEW $-0.41 -- THOMSON REUTERS I/B/E/S.  Full Article

aTyr Pharma reports qtrly ‍net loss per share, basic and diluted $0.43​
Wednesday, 15 Nov 2017 

Nov 14 (Reuters) - aTyr Pharma Inc ::aTyr Pharma announces third quarter 2017 operating results and provides corporate update.aTyr Pharma Inc - ‍expects that its cash, cash equivalents and investments will be sufficient to fund its anticipated operations into middle of 2019​.aTyr Pharma Inc qtrly ‍net loss per share, basic and diluted $0.43​.Q3 earnings per share view $-0.50 -- Thomson Reuters I/B/E/S.  Full Article

Atyr Pharma says ‍John Mendlein transitions from CEO to non-executive board member​
Thursday, 2 Nov 2017 

Nov 1 (Reuters) - Atyr Pharma Inc ::Atyr Pharma announces leadership transition.Atyr Pharma Inc - ‍John Mendlein transitions from CEO to non-executive board member​.Atyr Pharma Inc - ‍Sanjay Shukla appointed president and CEO​.  Full Article